Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2023 | Recent updates from the MajesTEC-4 trial

Elena Zamagni • 11 May 2023
COMy 2023
Multiple Myeloma Antibodies BiTEs Lenalidomide Teclistamab
MajesTEC-4

Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, shares some updates from the ongoing Phase III MajesTEC-4 trial (NCT05243797), which is comparing teclistamab in combination with lenalidomide versus lenalidomide alone or teclistamab alone as maintenance therapy in patients with newly diagnosed multiple myeloma (NDMM). This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Elena Zamagni

Evolution of risk stratification in SMM & MGUS: CTCs & imaging techniques
Bruno Paiva et al. • 25 Mar 2024
1:23
Combining MRD assays with functional imaging in multiple myeloma
Elena Zamagni • 28 Sep 2023
1:21
The impact of MRD standardized assessment by FDG-PET/CT in patients enrolled in the FORTE trial
Elena Zamagni • 28 Sep 2023
2:29
The role of various imaging techniques in multiple myeloma & the importance of optimizing these
Elena Zamagni • 28 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals